Q&A with Steve Gardner, CEO and Co-founder, PrecisionLife
Precision Medicine Quarterly
The era of precision medicine is taking over drug discovery and development. This patient‑centric approach has already transformed oncology and will inevitably transform much more prevalent and expensive chronic conditions, but to achieve this we will need a radically different view of these diseases and improved approach to R&D.
Chronic diseases, which account for 85% of healthcare costs, still have significant remaining pockets of unmet medical need that cause significant reductions in quality of life for patients, and high socioeconomic burdens.
In this Q&A with Precision Medicine Quarterly, Steve Gardner, CEO and Co-founder, PrecisionLife provides insight into the opportunity for precision neuroscience to revolutionize drug discovery and healthcare and how this vision is being realized through the understanding of complex disease biology using combinatorial analytics.
Precision Medicine Quarterly | Volume 1 | Issue 1 | March 2023
